MARSEILLE, France--(BUSINESS WIRE)--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced the first patient was dosed in its Phase 1 study ...
Our immune system is divided into two main branches: innate and adaptive. Innate immune cells act as a first line of defense, quickly responding to invaders, while adaptive immune cells take a longer ...
SARS-CoV-2 has an enzyme that can counteract a cell's innate defense mechanism against viruses, explaining why it is more infectious than the previous SARS and MERS-causing viruses. The discovery may ...
Researchers from the University of Osaka have demonstrated that mitochondrial hyperfusion, when induced by low levels of DRP1 ...
The novel coronavirus SARS-CoV-2 has an enzyme that can counteract a cell's innate defense mechanism against viruses, explaining why it is more infectious than the previous SARS and MERS-causing ...
Back in September, IPH6501 wasn’t named among the most valued candidates in Innate’s pipeline. (Bet_Noire/iStock/Getty Images Plus) Innate Pharma has finally called time on an NK cell engager in phase ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results